This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
If You Invested $1000 in Illumina 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Looking for a Growth Stock? 3 Reasons Why Illumina (ILMN) is a Solid Choice
by Zacks Equity Research
Illumina (ILMN) possesses solid growth attributes, which could help it handily outperform the market.
Illumina (ILMN) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Year-over-year improvement in segmental revenues in Q2 across all geographies exceeds Illumina's (ILMN) expectations.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Illumina (ILMN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 37.50% and 11.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN
by Zacks Equity Research
Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.
AMN Healthcare (AMN) to Report Q2 Earnings: What to Expect?
by Zacks Equity Research
Continued strength in AMN Healthcare's (AMN) staffing services is expected to have driven up Q2 sales.
Quidel (QDEL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have registered solid product sales during Q2 which are likely to have driven its overall top line.
What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment is expected to have driven up Q3 sales.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases second-quarter 2021 results.
Editas (EDIT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) second-quarter earnings call, investor focus will likely be on the company's progress with the development of EDIT-101, its lead pipeline candidate.
Canopy Growth (CGC) to Report in Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.
Is a Beat in the Cards for CVS Health (CVS) in Q2 Earnings?
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital approach to administer vaccines across the nation is expected to have strongly contributed to its Q2 performance within retail segment.
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.
Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on earnings and revenues when it releases second-quarter 2021 results.
What's in Store for Henry Schein (HSIC) in Q2 Earnings?
by Zacks Equity Research
Henry Schein's (HSIC) PPE sales from medical business are likely to have maintained momentum in Q2. Also, global recovery trends of its dental business are expected to reflect on Q2 results.
Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) second-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and pipeline progress.
How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.
What's in the Cards for Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) second-quarter results are likely to reflect improving revenues stemming from growing patient admissions, partly offset by high costs.
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued strength in the Global Healthcare and Life Sciences segment.
3 Reasons Why Growth Investors Shouldn't Overlook Illumina (ILMN)
by Zacks Equity Research
Illumina (ILMN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.